PDGFRA and hepatocellular carcinoma: As Govaere et al. 55 demonstrated that CK19 could be progressed through PDGFRα-LAMB1-CK19 axis, inhibitors of PDGFRα such as imatinib 76, regorafenib 77 and lenvatinib 78 might exert specific effect on CK19-positive HCC.